← BLOG
Medtech
·
October 21, 2026
·
5
min

Medtech: if regulatory is blocking your marketing, the problem lies elsewhere

Every piece of collateral stuck in review for weeks? Regulatory is rarely the real bottleneck, which usually lies in the lack of a messaging foundation approved upfront.

You have a solid product and a committed team, and yet every brochure, every web page and every post stays stuck for weeks between marketing and regulatory. The back-and-forth never ends, sales are waiting for their materials and the launch ends up slipping.

The instinct is then to blame regulatory, even though that is rarely the right diagnosis. Most of the time the bottleneck lies elsewhere, and more precisely in the lack of a messaging foundation approved upfront, so that every piece of collateral starts from scratch, and so does every regulatory review.

Why every piece gets stuck in review

In medtech, every piece of collateral must go through regulatory before it is released, which is normal and non-negotiable. The problem lies rather in the way marketing gets there.

Two habits drag the approval cycles out:

  • Numbers first. A scientific culture pushes you to back everything with figures, but every figure you put forward must be supported by a study that proves it, so every figure you add means one more check.
  • Form before substance. A fully designed brochure gets produced before being submitted, and a single rejected phrase is enough for the whole piece to be redone.

Every piece of collateral thus becomes a fresh negotiation with regulatory.

From a scientific culture to a commercial company

The urge to put numbers and scientific evidence front and center comes from the very culture of medtech. Founders often have scientific backgrounds and live through their studies, which do have real comparative value.

But a medtech company coming to market has to turn into a commercial company in order to run an effective, consistent go-to-market, and that work goes through marketing and product marketing.

Your prospect first needs to understand:

  • what your company does;
  • what your products do;
  • how they fit into their workflows, in the hospital, the lab or elsewhere;
  • what changes for each of your personas.

Scientific evidence comes next, as the conversation progresses, and it is backed by dedicated content such as scientific publications, webinars or conference talks. This is not about giving up on science, but about placing it at the right point in the buyer journey.

Get the foundation approved, not every single piece

The heart of the matter is having, from day one, a messaging that is consistent, unique, simple and strong, and that comes out of the go-to-market work done upfront:

  1. personas and ICP;
  2. the positioning platform;
  3. the offer hierarchy;
  4. the semantic and SEO strategy, built on the positioning platform.

These naturally lead to a brand book, visual and above all semantic, with fixed wording.

This foundation is what you get approved by regulatory, and all your language then flows from it. The materials you create afterwards, whether marketing, communications or product marketing, get approved faster, because they rest on a sound, shared and already-approved base.

The grey zone: marketing's call

You need to tell apart what falls under the rules themselves from what falls into a grey zone. A grey zone doesn't mean something is forbidden, it rather reflects a lack of information on the regulatory side.

In that case, marketing should be able to take the lead on the decision, while staying aligned with the positioning platform and the product marketing already approved. Without a foundation that decision can't be defended, whereas with an approved foundation it becomes a reasoned one.

Approve substance before form

Review time always depends on how responsive the teams are, on both the marketing and regulatory sides, but a clear process between the two smooths the exchanges and prevents mistakes.

The rule is simple: focus first on content and structure, and get that approved. Any visual design comes afterwards, whatever the marketing or product marketing asset.

  1. Write the content and structure from the approved foundation.
  2. Get that substance approved by regulatory.
  3. Only then start design and adaptations.

One message, several countries

The rules differ from place to place, between the United States and Europe but also within Europe itself.

The gap between the US and France is striking. In the US, you can compare yourself directly with a competing solution to demonstrate some form of superiority, as long as you can prove it, an approach familiar from American advertising that extends all the way to medtech. In France, the exercise is far more restricted.

These differences are best handled when building the foundation, rather than piece by piece.

FAQ

Who should have the final say in the grey zone?

Marketing, as long as the decision sits within the framework already approved, namely the positioning platform and product marketing. What falls under the rules themselves stays with regulatory.

Can you communicate without a clinical study?

Yes, about what your product does, how it fits into your customers' workflows and what it changes for your personas. Any figure you put forward, however, must be backed by a study.

Where should you start to speed up approvals?

With the positioning platform and the offer hierarchy, because that is the foundation everything else flows from, including the semantic brand book to get approved.

How Plan B can help

Plan B supports medtech companies on their go-to-market and branding, to lay down this messaging foundation and get it approved upfront. An audit takes stock of your current positioning and of what is slowing down your approvals.

KEY TAKEAWAYS
  • A messaging foundation approved once and for all speeds up every approval that follows.
  • Substance gets approved before the form is produced, whatever the asset.
  • Scientific evidence comes second, once the market has understood what you do.

Medtech

Structuring B2B SaaS marketing for medtech companies, between regulatory requirements and long decision cycles.

FACING THE SAME SITUATION?

BOOK A CALL